Vidya B Yalamanchi, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 200 Medical Center Dr, Hazard, KY 41701 Phone: 606-487-7510 Fax: 606-439-6793 |
Nageswara R Podapati, M.D. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 200 Medical Center Dr, Hazard, KY 41701 Phone: 606-439-4878 |
Srinivasa R Appakondu, M.D. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 243 Roy Campbell Dr Ste B, Hazard, KY 41701 Phone: 606-439-0051 Fax: 606-439-0516 |
News Archive
Morgan Ellison and Madison McDaniel were diagnosed with a rare germ cell tumor of the ovary earlier this year. The two strangers would soon form a unique bond during their treatment in Birmingham, Alabama.
ARIAD Pharmaceuticals, Inc. today announced that it is discontinuing the Phase 3 EPIC (Evaluation of Ponatinib versus Imatinib in Chronic Myeloid Leukemia) trial of Iclusig (ponatinib) in patients with newly diagnosed chronic myeloid leukemia.
Oxygen and glucose are the food of our brain. If they are absent, such as during a stroke, nerve cells die. An international research team at Charité - Universitätsmedizin Berlin, Germany, and McMaster University, Canada, has discovered a novel mechanism to prevent this cell death. The results of the study have now been published in the journal Proceedings of the National Academy of Sciences of the USA.
Titan Pharmaceuticals, Inc. today announced the initiation of a randomized, placebo and active controlled, multi-center Phase 3 clinical study of Probuphine in the treatment of opioid addiction. This confirmatory Phase 3 study will be conducted at approximately 23 sites in the United States and randomize approximately 250 patients into three arms: Probuphine (100 patients), Suboxone® (100 patients) and placebo (50 patients).
› Verified 6 days ago